The anti-IL-7R antibody-drug conjugate (A7R-ADC) has an anti-tumor effect on lymphatic malignancies and can target steroid-sensitive and -resistant cells; therefore, A7R-ADC could be a hopeful new choice for cancer treatment [132]. Here, IL7R is linked to neoplasm.